| Literature DB >> 34336237 |
Karolina Semczuk-Kaczmarek1, Anna Rys-Czaporowska1, Anna E Platek2, Filip M Szymanski3.
Abstract
INTRODUCTION: The presence of lower urinary tract symptoms (LUTS) might be linked with elevated cardiovascular risk. There is a lack of data showing the prevalence of LUTS in the population of patients with cardiovascular diseases. The current study aimed to determine the prevalence of LUTS in patients hospitalized due to a cardiovascular disease.Entities:
Keywords: cardiovascular risk; lower urinary tract symptoms; risk scores
Year: 2021 PMID: 34336237 PMCID: PMC8318018 DOI: 10.5173/ceju.2021.0370.R1
Source DB: PubMed Journal: Cent European J Urol ISSN: 2080-4806
Demographic and clinical characteristics of all patients (n = 166)
| Parameter | Value (mean ±SD) |
|---|---|
| Age (years) | 62.8 ±12.1 |
| BMI (kg/m2) | 28.8 ±16.6 |
| Arterial hypertension | 121 (72.9%) |
| Atrial fibrillation | 51 (30.7%) |
| Coronary artery disease | 119 (71.7%) |
| History of myocardial infarction | 75 (45.2%) |
| History of stroke | 11 (6.6%) |
| Heart failure | 79 (47.6%) |
| Diabetes mellitus | 52 (31.3%) |
| Peripheral artery disease | 13 (7.8%) |
| Glucose (mg/dL) | 123 ±55.3 |
| HbA1C (%) | 6.2 ±1.4 |
| Urea (mg/dL) | 42.8 ±21.5 |
| Creatinine (mg/dL) | 1.2 ±0.5 |
| eGFR (ml/min/1.73 m2) | 73.6 ±21.2 |
| Uric acid (mg/dL) | 6.3 ±1.8 |
| NT-proBNP (pg/mL) | 1567.9 ±3369.8 |
| CRP (mg/L) | 8.5 ±17.1 |
| PSA (ng/mL) | 2.3 ±8.6 |
| TSH (µIU/mL) | 1.9 ±1.1 |
BMI – body mass index; HbA1C – hemoglobin A1C; SD – standard deviation; eGFR – estimated glomerular filtration rate; NT-proBNP – N-terminal B-type natriuretic peptide; CRP – C-reactive protein; PSA – prostate-specific antigen; TSH – thyroid-stimulating hormone
Demographic and clinical characteristics – comparison of subgroups separated based on the presence of LUTS
| Parameter | Patients without LUTS (n = 104) | Patients with moderate to severe LUTS (n = 62) | p value |
|---|---|---|---|
| Age (years) | 60.3 ±12.6 | 66.9 ±10.0 | <0.001 |
| BMI (kg/m2) | 28.8 ±6.5 | 28.7 ±4.2 | 0.40 |
| Arterial hypertension | 72 (69.2%) | 49 (79.0%) | 0.21 |
| Atrial fibrillation | 32 (30.8%) | 19 (30.6%) | 1.00 |
| Coronary artery disease | 71 (68.3%) | 48 (77.4%) | 0.22 |
| History of myocardial infarction | 46 (44.2%) | 29 (46.8%) | 0.87 |
| History of stroke | 9 (8.7%) | 2 (3.2%) | 0.21 |
| Heart failure | 54 (51.9%) | 25 (40.3%) | 0.15 |
| Diabetes mellitus | 30 (28.8%) | 22 (35.5%) | 0.39 |
| Peripheral artery disease | 11 (10.6%) | 2 (3.2%) | 0.13 |
| Glucose (mg/dL) | 126.1 ±59.7 | 117.8 ±47.1 | 0.65 |
| HbA1C (%) | 6.1 ±1.4 | 6.3 ±1.4 | 0.06 |
| Urea (mg/dL) | 42.1 ±23 | 43.9 ±19.2 | 0.21 |
| Creatinine (mg/dL) | 1.2 ±0.5 | 1.2 ±0.6 | 0.34 |
| eGFR (ml/min/1.73m2) | 74 ±21.2 | 73 ±21.4 | 0.86 |
| Uric acid (mg/dL) | 6.3 ±2.0 | 6.2 ±1.4 | 0.74 |
| NT-proBNP (pg/mL) | 1471.6 ±2747.1 | 1729.0 ±4232.5 | 1.00 |
| CRP (mg/L) | 7.7 ±16.8 | 9.7 ±17.6 | 0.59 |
| PSA (ng/mL) | 1.5 ±2.2 | 3.5 ±13.8 | 0.32 |
| TSH (µIU/mL) | 1.9 ±1.1 | 2.1 ±1.2 | 0.18 |
LUTS – lower urinary tract symptoms; BMI – body mass index; eGFR – estimated glomerular filtration rate; NT-proBNP – N-terminal B-type natriuretic peptide; CRP – C-reactive protein; PSA – prostate-specific antigen; TSH – thyroid-stimulating hormone; HbA1C – hemoglobin A1C; SD – standard deviation
Comparison of patients according to the LUTS severity
| Parameter | LUTS severity according to IPSS | p value | ||
|---|---|---|---|---|
| None or mild n = 104 | Moderate n = 49 | Severe n = 13 | ||
| Age (years) | 60.3 ±12.5 | 66.2 ±10.6 | 70.8 ±6.2 | 0.001 |
| BMI (kg/m2) | 28.8 ±6.5 | 28.9 ±4.5 | 28.1 ±3.1 | 0.58 |
| Arterial hypertension | 73 (69.5%) | 35 (72.9%) | 13 (100%) | 0.07 |
| Atrial fibrillation | 32 (30.5%) | 17 (35.4%) | 2 (15.4%) | 0.38 |
| Coronary artery disease | 72 (68.6%) | 35 (72.9%) | 12 (92.3%) | 0.20 |
| History of myocardial infarction | 46 (43.8%) | 23 (47.9%) | 6 (46.2%) | 0.89 |
| History of stroke | 9 (8.6%) | 2 (4.2%) | 0 (0%) | 0.36 |
| Heart failure | 54 (51.4%) | 20 (41.7%) | 5 (38.5%) | 0.42 |
| Diabetes mellitus | 31 (29.5%) | 16 (33.3%) | 5 (38.5%) | 0.76 |
| Peripheral artery disease | 11 (10.5%) | 2 (4.2%) | 0 (0%) | 0.22 |
| Glucose (mg/dL) | 126.1 ±59.4 | 120.7 ±52.1 | 106.9 ±23.2 | 0.83 |
| HbA1C (%) | 6.1 ±1.4 | 6.3 ±1.5 | 6.4 ±1.4 | 0.13 |
| Urea (mg/dL) | 42.1 ±23 | 44.4 ±18.2 | 41.9 ±23 | 0.38 |
| Creatinine (mg/dL) | 1.2 ±0.5 | 1.1 ±0.4 | 1.4 ±1.2 | 0.54 |
| eGFR (ml/min/1.73m2) | 73.8 ±21.1 | 74.2 ±20.9 | 69.2 ±24.2 | 0.83 |
| Uric acid (mg/dL) | 6.3 ±2 | 6.2 ±1.4 | 6.1 ±1.5 | 0.99 |
| NT-proBNP (pg/mL) | 1458.6 ±2736.8 | 1853.9 ±4647.7 | 1400.2 ±2524.8 | 0.98 |
| CRP (mg/L) | 7.7 ±16.8 | 8.3 ±15.4 | 15.3 ±24.4 | 0.40 |
| PSA (ng/mL) | 1.5 ±2.1 | 3.9 ±15.9 | 2.3 ±2.3 | 0.11 |
| TSH (µIU/mL) | 1.9 ±1 | 2.2 ±1.3 | 1.6 ±0.5 | 0.25 |
LUTS – lower urinary tract symptoms; IPSS – International Prostate Symptom Score; BMI – body mass index; eGFR – estimated glomerular filtration rate; NT-proBNP – N-terminal B-type natriuretic peptide; CRP – C-reactive protein; PSA – prostate-specific antigen; TSH – thyroid-stimulating hormone ; HbA1C – hemoglobin A1C; SD – standard deviation
Figure 1IPSS score according to the chief complaint on admission.